CLGNHealthcare · BiotechnologyTicker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 34 of 100 as at 14 Sept 2026 — in the lower half.
Consensus tells you what everyone already believes. The model scores CollPlant Biotechnologies Ltd. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (94): Smaller than most of the companies we track.
Value (6): The shares cost a lot relative to the profits and assets behind them.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on CLGN, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 6 Feb 2026 | D. Boral Capital | Downgrade | Hold | — |
| 28 Nov 2025 | D. Boral Capital | Maintains | Buy | — |
| 20 Oct 2025 | D. Boral Capital | Maintains | Buy | — |
| 16 Sept 2025 | D. Boral Capital | Maintains | Buy | — |
| 21 Aug 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 20 Aug 2025 | D. Boral Capital | Maintains | Buy | — |
| 30 May 2025 | D. Boral Capital | Maintains | Buy | — |
| 28 May 2025 | D. Boral Capital | Maintains | Buy | — |
| 27 Mar 2025 | D. Boral Capital | Maintains | Buy | — |
| 12 Feb 2025 | D. Boral Capital | Maintains | Buy | — |
| 4 Feb 2025 | D. Boral Capital | Maintains | Buy | — |
| 29 Nov 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 27 Nov 2024 | D. Boral Capital | Maintains | Buy | — |
| 21 Aug 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 20 Aug 2024 | EF Hutton | Maintains | Buy | — |
| 5 Aug 2024 | EF Hutton | Initiates | Buy | — |
| 30 May 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 5 Apr 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 30 Nov 2023 | HC Wainwright & Co. | Reiterates | Buy | — |
| 25 Aug 2023 | HC Wainwright & Co. | Reiterates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. CLGN appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 14 Sept 2026, CollPlant Biotechnologies Ltd. returned −86.7% against +17.0% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 88% of US stocks
Cheaper than 10% of US stocks
Cheaper than 72% of US stocks
Cheaper than 62% of US stocks
Higher than 2% of US stocks
Higher than 1% of US stocks
Higher than 3% of US stocks
Higher than 97% of US stocks
Higher than 9% of US stocks
Higher than 6% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
CollPlant Biotechnologies Ltd. has a market value of $6.6M and an enterprise value of $3.4M.
Revenue in the twelve months to 31 Mar 2026: $389K. The latest quarter shrank 96.4% year on year.
Net income over the same four quarters: −$13.1M, a −3376.3% net margin.
Free cash flow in the twelve months to 31 Mar 2026: −$11.3M, after $25K of capital spending.
Trailing P/E: −3.7×; forward P/E: −8.9× — the forward figure prices analyst consensus estimates, not reported earnings.
CollPlant Biotechnologies Ltd. employs 39 people — $10K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own CollPlant Biotechnologies Ltd. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
CollPlant Biotechnologies announced it will host a LightSolver investor webinar on September 17, 2026. The announcement was made via PRNewswire from the company's Rehovot, Israel headquarters.
Why it matters — This gives CLGN watchers a scheduled opportunity to hear directly from the company about its LightSolver initiative and current business direction.
CollPlant Biotechnologies announced the appointment of Dr. Ruti Ben Shlomi to its Board of Directors following the closing of its acquisition of LightSolver. Dr. Ben Shlomi, LightSolver's Founder and CEO, brings scientific and entrepreneurial expertise as the company advances commercialization of the acquired photonic computing technology.
Why it matters — CLGN watchers would care because adding LightSolver's founder and CEO to the board signals leadership continuity and expertise as the company commercializes its newly acquired photonic computing technology.
CollPlant Biotechnologies has completed its acquisition of LightSolver, entering the photonic computing sector. LightSolver is developing what it describes as a Laser Processing Unit (LPU), an energy-efficient, pure photonic computing platform, and the transaction is expected to accelerate its path toward commercialization and expand partnerships.
Why it matters — This acquisition marks a significant strategic expansion for CollPlant beyond its biotechnology focus, opening a new commercial growth avenue through LightSolver's energy-efficient photonic computing technology.
CollPlant Biotechnologies Ltd. has announced a reverse share split, as reported in a press release dated September 1, 2026, from Rehovot, Israel. The announcement was published via PRNewswire.
Why it matters — A reverse share split is a structural corporate action that affects CLGN's share count and price per share, so shareholders would want to track its implementation.
CollPlant is acquiring LightSolver, a company pioneering pure photonic computing with its Laser Processing Unit, which aims to address the speed, energy, and heat limitations of semiconductor-based computing. LightSolver's technology combines advantages of classical and quantum computing in a compact platform designed for commercial deployment, with validation underway at companies including Boeing and leading defense, financial, and energy organizations.
Why it matters — This acquisition expands CollPlant into the emerging supercomputing and photonic computing markets, diversifying its business beyond its established biotechnology focus.
Of the 1 analysts covering CollPlant Biotechnologies Ltd., 0 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks CollPlant Biotechnologies Ltd. 34 out of 100 across roughly 4,600 US stocks as at 14 Sept 2026. None of this is personal advice — it does not consider your circumstances.
As at 14 Sept 2026, CollPlant Biotechnologies Ltd. ranks 34 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (94 of 100).
No analyst covering CollPlant Biotechnologies Ltd. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CLGN are extrapolating price history, which says nothing about the business.
CollPlant Biotechnologies Ltd. returned -86.7% over the 12 months to 14 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.
CollPlant Biotechnologies Ltd. is a regenerative and aesthetic medicine company focused on developing medical products based on its recombinant human collagen technology.
The most recent item we track (PRNewsWire, 10 Sept 2026): "CollPlant to Host LightSolver Investor Webinar on September 17, 2026". CollPlant Biotechnologies announced it will host a LightSolver investor webinar on September 17, 2026. The announcement was made via PRNewswire from the company's Rehovot, Israel headquarters.
CollPlant Biotechnologies Ltd. is a regenerative and aesthetic medicine company focused on developing medical products based on its recombinant human collagen technology. The company’s current portfolio centers on 3D bioprinting for tissues and organs, tissue repair, advanced wound care, and medical aesthetics. Its offerings include bioinks and collagen-based materials designed for regenerative applications, along with products used in soft tissue repair and wound management. CollPlant Biotechnologies also works with partners and collaborators in the broader medical device and biotech ecosystem, supporting applications in orthobiologics, surgical repair, and aesthetic medicine. Headquartered in Rehovot, Israel, CollPlant Biotechnologies Ltd. plays a niche role in the market by combining plant-based biotechnology with collagen innovation for healthcare uses.
CEO Mr. Yehiel Tal · 39 employees · Israel · https://collplant.com
